Claims for Patent: 8,623,418

Summary for Patent: 8,623,418

Title:	Pharmaceutical composition
Abstract:	Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated.
Inventor(s):	Liang; Alfred (Edison, NJ), Matthews; Frank (Edison, NJ), Boehm; Garth (Westfield, NJ), Tang; Lijuan (Flemington, NJ), Johnson; Frank (Bridgewater, NJ), Stauffer; Joseph (Skillman, NJ)
Assignee:	Alpharma Pharmaceuticals LLC (Bridgewater, NJ)
Application Number:	12/336,267
Patent Claims:	1. A method of treating moderate to severe chronic pain in a patient in need thereof comprising orally administering to the patient an intact multi-layer pharmaceutical composition comprising: a core; an opioid antagonist layer, coating the core; a sequestering polymer layer which contains a charge-neutralizing additive and a hydrophobicity-enhancing additive and which coats said opioid antagonist layer; an opioid agonist layer coating the sequestering polymer layer, and; an osmotic pressure regulating agent located immediately beneath the agonist layer; wherein administration of the intact form of the composition to the patient once or twice daily for a time period of at least two weeks results in zero release of the antagonist over the time period as determined by the antagonist concentration in the plasma of the patient. 2. The method of claim 1 wherein administration of the intact form of the composition to the patient for at least a time period selected from the group consisting of four, eight, 12, 16, 20, 24, 28, 32, 36, 40 and 100 weeks. 3. The method of either claim 1 or 2 wherein the antagonist is naltrexone. 4. The method of claim 3 wherein release of naltrexone is determined by measuring plasma levels of B-naltrexol. 5. A method of treating moderate to severe chronic pain in a patients in need thereof comprising orally administering to the patients an intact multi-layer pharmaceutical composition comprising: a core; an opioid antagonist layer, coating the core; a sequestering polymer layer which contains a charge-neutralizing additive and a hydrophobicity-enhancing additive and which coats said opioid antagonist layer; an opioid agonist layer coating the sequestering polymer layer, and; an osmotic pressure regulating agent located immediately beneath the agonist layer; wherein administration of the intact form of the composition to the patients once daily for a time period of at least two weeks results in zero release of the antagonist in about 90% of the patients as determined by measuring antagonist concentration in the plasma of the patients. 6. The method of claim 5 wherein administration of the intact form of the composition to the patient for at least a time period of 28 weeks. 7. The method of either claim 5 or 6 wherein the antagonist is naltrexone. 8. The method of claim 7 wherein release of naltrexone is determined by measuring plasma levels of B-naltrexol. 9. The method of claim 2 or 3 wherein the opioid agonist is morphine. 10. The method of claim 7 or 8 wherein the opioid agonist is morphine. 11. The method of claim 9 or 10 wherein the osmotic pressure regulating agent is hydroxypropyl methylcellulose or chloride ions. 12. The method of claim 1 wherein the opioid agonist is morphine and the opioid antagonist is naltrexone. 13. A method of treating moderate to severe chronic pain in a patients in need thereof comprising orally administering to the patients an intact multi-layer pharmaceutical composition comprising: a core; an opioid antagonist layer coating the core; a sequestering polymer layer which contains a charge-neutralizing additive and a hydrophobicity-enhancing additive and which coats said opioid antagonist layer; an opioid agonist layer coating the sequestering polymer layer, and an osmotic pressure regulating agent located immediately beneath the agonist layer; wherein administration of the intact form of the composition to the patients once daily for a time period of at least two weeks results in zero release of the antagonist in about 80% of the patients as determined by measuring antagonist concentration in the plasma of the patients. 14. The method of claim 13 wherein the osmotic pressure agent is sodium chloride.